(Q37247749)

19 August 2017

1 reference

title

Lessons from ONTARGET. (English)

1 reference

19 August 2017

V Berlaimont

1

1 reference

19 August 2017

J-M Billiouw

2

1 reference

19 August 2017

C Brohet

3

1 reference

19 August 2017

A G Dupont

4

1 reference

19 August 2017

M-D Gazagnes

5

1 reference

19 August 2017

F Heller

6

1 reference

19 August 2017

J M Krzesinski

7

1 reference

19 August 2017

L Missault

8

1 reference

19 August 2017

A Persu

9

1 reference

19 August 2017

L Piérard

10

1 reference

19 August 2017

R Rottiers

11

1 reference

19 August 2017

G Vanhooren

12

1 reference

19 August 2017

W Van Mieghem

13

1 reference

19 August 2017

P Vervaet

14

1 reference

19 August 2017

A G Herman

15

1 reference

19 August 2017

publication date

1 May 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

63

1 reference

19 August 2017

issue

3

1 reference

19 August 2017

page(s)

142-151

1 reference

Estimates of global and regional potential health gains from reducing multiple major risk factors

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

The global burden of chronic diseases: overcoming impediments to prevention and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Beyond blood pressure: new roles for angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Angiotensin-II-receptors: new targets for antihypertensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Changes in skin angiotensin II receptors in rats during wound healing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Important role of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

The AT2 receptor--a matter of love and hate

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Blood-pressure reduction and cardiovascular risk in HOPE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Antihypertensive therapy in the presence of proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

The ONTARGET/TRANSCEND Trial Programme: baseline data

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

2007 Guidelines for the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2008.025

21 January 2018

Identifiers

DOI

10.1179/ACB.2008.025

1 reference

19 August 2017

1 reference